Oct 2nd 2024
Novel mitophagy inducers and gene therapies that restore cellular function and decelerate the ageing process.
Mar 4th 2024
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Dec 3rd 2023
The bio/pharmaceutical industry is struggling with the challenge of staffing and training.
Sep 2nd 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
March 6th 2025
In an interview with Pharmaceutical Technology®, Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the M&A landscape from 2024 and his expectations of what is to come next.
February 10th 2025
Experts provide their insights into the trends that have shaped the global bio/pharma industry in 2024 and give their predictions as to what may be impactful in 2025 and beyond.
February 7th 2025
In this interview, Pharmaceutical Technology® discusses the trend of AI in pharma and how it may play out in 2025 and beyond with Ben Sidders from Biorelate.
January 24th 2025
The collaboration will combine fully automated and digitalized technologies to reduce CGT manufacturing timelines to 2.5 days.
January 22nd 2025
Cytiva will combine its CGT manufacturing technologies with Cellular Origins' robotic manufacturing platform.
January 17th 2025
Production is set to take place at Samsung Biologics’ Songdo, South Korea, site, and the agreement will run through December 2030, subject to change.
January 15th 2025
Lonza will work with Iconovo to develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity.
January 8th 2025
Vanessa Almendro, Elliot Berger, Benjamin McCloud, and Turna Ray go behind the headlines to discuss 2024’s biggest trends in the pharmaceutical industry, as well as the unforeseen outcomes that took us by surprise.
January 3rd 2025
Under the agreement, the companies will advance development of IBI3009, Innovent’s ADC candidate, which has received IND approvals in the US, China, and Australia.
December 20th 2024
The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.